Floatz logo

DOTA-PABZA-DIG-DPHE-GLN-TRP-ALA-VAL-GLY-HIS-NHCH(CH2CH(CH3)2)2

Newly Diagnosed and Recurrent Glioblastoma

Novartis Pharmaceuticalsprotein_peptidePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

353 Active assets in the Newly Diagnosed and Recurrent Glioblastoma cohort.

Asset / SponsorPhaseRating
Irinotecan
Beijing Sanbo Brain Hospital
Phase 2/3BBB
Depatuxizumab Mafodotin
AbbVie
Phase 3BB
CARMUSTINE
Leland Metheny
Phase 3BB
Irinotecan
University of Cincinnati
Phase 3BB
(+)-VINCRISTINE
University of Cincinnati
Phase 3BB

View all 50 →

Same molecule, other indications

DOTA-PABZA-DIG-DPHE-GLN-TRP-ALA-VAL-GLY-HIS-NHCH(CH2CH(CH3)2)2 is also rated in:

breast cancerDormant
CCC
Indicative ·
53 / 100
View asset →
non-small cell lung carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →
small cell lung carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →